Annual report pursuant to Section 13 and 15(d)

Reorganization and Recapitalization

v3.21.2
Reorganization and Recapitalization
12 Months Ended
Dec. 31, 2020
Restructuring and Related Activities [Abstract]  
REORGANIZATION AND RECAPITALIZATION

NOTE 4 — REORGANIZATION AND RECAPITALIZATION


On July 16, 2019, 180 and each of 180 LP, Katexco and CBR Pharma completed a corporate restructuring, pursuant to which 180 LP, Katexco and CBR Pharma became wholly-owned subsidiaries of 180 (the “Reorganization”). It was determined that Katexco was the accounting acquirer in the Reorganization and the remaining companies were the accounting acquirees.


In connection with the Reorganization, the Company issued an aggregate of 9,881,785 shares of common stock, and 1 share of preferred stock which is exchangeable into an aggregate of 1,664,083 shares of common stock at the option of the holders, to the former shareholders of CBR Pharma and 180 LP, in exchange for 100% of the outstanding equity and equity equivalents of CBR Pharma and 180 LP. Of the 9,881,785 shares of common stock issued in connection with the Reorganization, 2,694,053 shares were issued to a consultant were subject to redemption by 180 LP (the “Contingently Redeemable Shares”) for an aggregate redemption price of $4.00 if (i) the closing of the Business Combination did not occur on or prior to October 31, 2019; or (iii) the consultant terminated its service with 180 LP prior to October 31, 2019. On November 11, 2019, the Board of Directors authorized its management to enter into an agreement to waive its right of redemption in connection with the Contingently Redeemable Shares. Note 15 - Stockholders’ Equity (Deficiency), Contingently Redeemable Shares.


The Reorganization was accounted for as a reverse acquisition using the acquisition method of accounting, with Katexco being the accounting acquirer for financial reporting purposes.


The following table summarizes the purchase price consideration paid to the accounting acquirees:


    CBR Pharma     180 LP     Total  
Debt assumed   $ -     $ 270,000     $ 270,000  
Shares at fair value (a)     24,927,274       20,939,224       45,866,498  
Total Purchase Consideration   $ 24,927,274     $ 21,209,224     $ 46,136,498  

a) Represents the fair value of 3,965,059 and 1,326,830 shares of common stock and common stock equivalents issued to the former shareholders of CBR Pharma and 180 LP, respectively. The value of the Contingently Redeemable Shares was not accounted for since, as of the date of the Reorganization, it was not probable that the conditions for which the redemption provision could be removed would be met.

The following table represents the preliminary allocation of the assets acquired and liabilities assumed, based on their fair values on the acquisition date:


    CBR Pharma     180     Total  
Cash   $ 47,268     $ 38,810     $ 86,078  
Prepaid expenses (1)     126,606       595,849       722,455  
Other receivables     -       420,000       420,000  
Deposits     86,192       -       86,192  
Property and equipment     47,958       -       47,958  
Technology licenses (2)     1,609,000       -       1,609,000  
In process research and development (2)     1,584,000       10,943,000       12,527,000  
Due from (to) related parties     783,593       (555,100 )     228,493  
Accounts payable and accrued expenses     (1,528,894 )     (134,081 )     (1,662,976 )
Deferred income, related party (3)     (36,537 )     (492,329 )     (528,866 )
Deferred tax liabilities (4)     (832,000 )     (2,845,180 )     (3,677,180 )
Net fair value of assets acquired and liabilities assumed     1,887,186       7,970,969       9,858,154  
Goodwill (2)     23,040,089       13,238,255       36,278,344  
Total   $ 24,927,275     $ 21,209,224     $ 46,136,498  

(1) Includes $588,349 related to prepaid research and development expenses with Oxford University. See Note 14 – Commitments and Contingencies.

(2) Changes in the balance of technology licenses, in process research and development and goodwill reflected on the balance sheet are the result of the impact of the change in foreign currency exchange rates.

(3) Represents deferred income associated with the 360 Life Sciences Corp. agreement (formerly known as the “Reformation Pharmaceuticals” agreement). See Note 14 – Commitments and Contingencies.

(4) See Note 16 – Income Taxes for more information on deferred tax liabilities.

Management, with the assistance of an independent valuation firm, valued the technology licenses and the in-process research and development utilizing the cost approach. The goodwill is attributed to (a) synergies arising from the overlap of clinical research among the entities; (b) the benefit of future market, drug and product development; and (c) the benefit of revenue growth from both areas. The deferred tax liability relates to the book-tax basis difference associated with the intangible assets at an estimated tax rate of 26%, which is an estimate of the blended United States and Canadian federal and state/province effective income tax rates.


Pro Forma Results


The following table sets forth the unaudited pro forma results of the Company as if the Reorganization were effective on January 1, 2019. These combined results are not necessarily indicative of the results that may have been achieved had the companies always been combined.


    For the
Year Ended
 
    December 31,
2019
 
Revenues   $ -  
Operating loss   $ (25,300,321 )
Net loss   $ (29,437,823 )